J. Chon

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1‐based therapy

R. Sullivan, Douglas B. Johnson, A. Shoushtari, 2018, Cancer.

Biomarkers for immune therapy in melanoma

Douglas B. Johnson, J. Balko, Mark R. Johnson, 2018, Seminars in cutaneous medicine and surgery.

Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who have received PD-1 based therapy.

R. Sullivan, Douglas B. Johnson, A. Shoushtari, 2018 .